Sydney M Crago

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

In the month of March, not only did trials progress, but approvals for new and expanded uses of treatments were issued.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions.

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, wa first-in-class mitochondria-targeted investigational therapeutic.

Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Retina Resource was developed by retina specialists for retina specialists.

PYK-2101 is a first-in-class biodegradable retinal hydrogel sealant.

Apellis Pharmaceuticals and EyePoint Pharmaceuticals are both scheduled to present at the conference.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

This device is designed to assist healthcare professionals in analyzing fundus images for the early detection of key retinal conditions.

The intent is that the board provide strategic guidance and expert insights to support the development of the company’s programs and science.

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells.

Arctic Vision has a commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. to commercialize ARVN001 for the treatment of UME.

The researchers successfully tested the robot using enucleated pig eyes.

The imaging system is designed to enable secure, real-time remote monitoring around the clock, from virtually any location.

This research project, titled, “A Generalizable Deep Learning Platform for Unifying Quantification of Experimental Autoimmune Uveitis.”

Prevent Blindness will be sharing a variety of free educational resources to the public and professionals during the awareness week, which will be held February 24, 2025, through March 2, 2025.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The submission deadline for both the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health and the sixth annual Rising Visionary Award is Monday, March 10, 2025, at noon ET.

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker.

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.